Is the amyloid cascade hypothesis still the best explanation for AD?

## My Position: The Hypothesis Has Survived But Evolved Beyond Its Original Form The cascade hypothesis remains *serviceable* but is no longer *dominant*—and those are different things. **The core problem isn't that Aβ was wrong, it's that the model was too linear.** Framing amyloid as the "first cause" implied a unidirectional disease, whereas the evidence increasingly supports a network of interacting pathologies (vascular, metabolic, inflammatory, TDP-43) where amyloid may be a *promoter* or *amplifier* rather than origin point. **Recent trial data is the key evidence here.** Lecanemab and donanemab demonstrate amyloid removal does produce measurable clinical benefit, which validates that amyloid is *relevant*. But the effect sizes are modest and disease progression continues despite amyloid clearance—suggesting it's neither necessary nor sufficient as the sole driver. This is consistent with a "multiple hits" framework where amyloid is one vulnerability among several (PMID: 36137926). **A distinctive reframe:** The cascade model was formulated before the field understood late-onset AD as heterogeneous. A 78-year-old with TDP-43 limbic-predominant age-related TDP-43 encephalopathy (LATE) and amyloid is not on the same disease trajectory as a 68-year-old with dominantly inherited APP mutation. Treating them as equivalent is the real failure mode—not the hypothesis itself. **My take:** The hypothesis has been *correctly revised* to something like "Aβ initiates or accelerates a self-reinforcing neurodegenerative network." That's a fundamentally different claim than the original cascade, and arguably much more defensible. But calling it "the best explanation" requires acknowledging it now requires at least four co-authors (vascular, metabolic, inflammatory, aging). **Confidence: 0.75** — The field consensus is shifting, but the amyloid-centric funding and publication bias means the broader model hasn't fully propagated into mainstream clinical thinking yet.

# Skeptic's Assessment: The Amyloid Cascade Hypothesis ## Lead: Falsifiability Failure The amyloid cascade hypothesis (ACH) has not been *falsified* — it has been *disconfirmed* by Phase 3 trials. Multiple large trials of amyloid-lowering agents (bapineuzumab, solanezumab, semagacestat) failed to meet primary cognitive endpoints despite successfully reducing amyloid burden (PMID: **22665828**, **24906972**). A hypothesis whose core prediction — *reducing amyloid improves cognition* — has repeatedly failed is no longer "best explanation." It's the leading survivor of falsification, not its victor. --- ## Weaknesses in the Evidence ### 1. Correlation ≠ Causation The foundational evidence is epidemiological and neuropathological: elevated Aβ correlates with AD. This is the same logical trap that made cholesterol → heart disease the dominant model for decades until the data required revision. Early-onset familial AD shows Aβ buildup precedes symptoms, but this is a minority (~5%) of cases. For *sporadic* late-onset AD (95% of cases), Aβ accumulation may be a downstream consequence, not upstream cause (PMID: **29128392**). ### 2. Preclinical Accumulation with Normal Cognition Aβ plaques are detected by PET imaging in **20-40% of cognitively normal individuals over 65** (PMID: **18772504**). If Aβ is the cascade trigger, why do these individuals not progress to AD? This is not a minor confound — it's a falsification test the hypothesis has failed to pass. ### 3. Temporal Paradox If amyloid accumulation initiates a cascade leading to tau pathology, neurodegeneration, and cognitive decline over decades, why does removing amyloid in *mild-to-moderate* AD patients (the majority of trials) fail to halt progression? Either the cascade is already irreversible by symptomatic stages, or Aβ isn't the trigger. --- ## Counter-Evidence & Alternative Explanations ### The Vascular Hypothesis Has Stronger Explanatory Power for Sporadic AD - Cerebrovascular pathology (microinfarcts, white matter lesions, blood-brain barrier breakdown) shows stronger correlation with cognitive impairment than amyloid in some cohorts (PMID: **30585786**, **32271324**). - APOE4's effects on lipid transport and vascular function may explain its AD risk more parsimoniously than Aβ acceleration. - The SVD (small vessel disease) - AD overlap is >60% in neuropathological series. ### Neuroinflammation as Primary Driver - TREM2 variants (reducing microglial Aβ clearance) implicate immune dysfunction *early* in pathogenesis (PMID: **24670649**). - Human iPSC models show microglial-mediated Aβ phagocytosis as a key disease modifier. - The "Aβ first, inflammation second" model hasn't been definitively established in humans. ### Tau Spread Model Competes - Tau pathology correlates more strongly with cognitive decline than amyloid (PMID: **26646930**). - Synaptic loss precedes amyloid deposition in some longitudinal studies. - The hypothesis may have the causation reversed: Aβ accumulation may be a result of synaptic failure and metabolic stress. --- ## Revised Confidence Score | Original confidence in ACH | Evidence quality | Revised confidence | |---|---|---| | ~0.85 for familial AD | Strong for early-onset | ~0.75 | | ~0.70 for sporadic AD | Multiple trial failures | ~0.35–0.40 | **ACH remains a plausible contributor to AD pathogenesis, particularly in early-onset familial forms. It is *not* the best explanation for sporadic late-onset AD, where vascular, inflammatory, and metabolic factors collectively appear more explanatory.** --- ## What Would Falsify Alternative Hypotheses? - Blocking tau seeding without affecting Aβ must improve outcomes in sporadic AD. - Demonstrating that vascular normalization (e.g., antihypertensives) halts Aβ accumulation in humans would invert causality. - Genetic evidence that *only* Aβ pathway genes (not vascular/immune genes) modify sporadic AD risk. --- ## Conclusion The amyloid cascade hypothesis has the historical advantage of being **first, most funded, and most tested**. That is not the same as being **best-supported**. Science progresses not by defending leading hypotheses but by subjecting them to the trials they've already failed. The field's continued investment in amyloid-centric therapies despite repeated disconfirmation is itself a candidate for scrutiny — a classic sunk-cost trap. The honest answer: **ACH explains some of AD, but much of the disease remains unexplained by this framework.**